SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:79aa491e-8aa0-4f69-b2d8-f9427ef30dfa"
 

Search: onr:"swepub:oai:lup.lub.lu.se:79aa491e-8aa0-4f69-b2d8-f9427ef30dfa" > The role of the pro...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Cremers, Ruben G.Radboud University Medical Center (author)

The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers

  • Article/chapterEnglish2015

Publisher, publication year, extent ...

  • Elsevier BV,2015

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:79aa491e-8aa0-4f69-b2d8-f9427ef30dfa
  • https://lup.lub.lu.se/record/79aa491e-8aa0-4f69-b2d8-f9427ef30dfaURI
  • https://doi.org/10.1016/j.urolonc.2015.01.018DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Objective: To evaluate the additive value of the prostate cancer gene 3 (PCA3) urine test to serum prostate-specific antigen (PSA) in prostate cancer (PC) screening among breast cancer, early-onset gene (BRCA) mutation carriers. This study was performed among the Dutch participants of IMPACT, a large international study on the effectiveness of PSA screening among BRCA mutation carriers. Materials and methods: Urinary PCA3 was measured in 191 BRCA1 mutation carriers, 75 BRCA2 mutation carriers, and 308 noncarriers. The physicians and participants were blinded for the results. Serum PSA level≥3.0. ng/ml was used to indicate prostate biopsies. PCA3 was evaluated (1) as an independent indicator for prostate biopsies and (2) as an indicator for prostate biopsies among men with an elevated PSA level. PC detected up to the 2-year screening was used as gold standard as end-of-study biopsies were not performed. Results: Overall, 23 PCs were diagnosed, 20 of which were in men who had an elevated PSA level in the initial screening round. (1) PCA3, successfully determined in 552 participants, was elevated in 188 (cutoff≥25; 34%) or 134 (cutoff≥35; 24%) participants, including 2 of the 3 PCs missed by PSA. PCA3 would have added 157 (≥25; 28%) or 109 (≥35; 20%) biopsy sessions to screening with PSA only. (2) Elevated PCA3 as a requirement for biopsies in addition to PSA would have saved 37 (cutoff≥25) or 43 (cutoff≥35) of the 68 biopsy sessions, and 7 or 11 PCs would have been missed, respectively, including multiple high-risk PCs. So far, PCA3 performed best among BRCA2 mutation carriers, but the numbers are still small. Because PCA3 was not used to indicate prostate biopsies, its true diagnostic value cannot be calculated. Conclusions: The results do not provide evidence for PCA3 as a useful additional indicator of prostate biopsies in BRCA mutation carriers, as many participants had an elevated PCA3 in the absence of PC. This must be interpreted with caution because PCA3 was not used to indicate biopsies. Many participants diagnosed with PC had low PCA3, making it invalid as a restrictive marker for prostate biopsies in men with elevated PSA levels.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Eeles, Rosalind A.Institute of Cancer Research London,Royal Marsden NHS Foundation Trust (author)
  • Bancroft, E. K.Institute of Cancer Research London,Royal Marsden NHS Foundation Trust (author)
  • Ringelberg-Borsboom, JannekeThe Netherlands Foundation for the Detection of Hereditary Tumours (author)
  • Vasen, Hans F.The Netherlands Foundation for the Detection of Hereditary Tumours (author)
  • Van Asperen, Christi J.Leiden University Medical Centre (author)
  • Schalken, Jack A.Radboud University Medical Center (author)
  • Verhaegh, Gerald W.Radboud University Medical Center (author)
  • Kiemeney, Lambertus A.Radboud University Medical Center (author)
  • Aaronson, N.Netherlands Cancer Institute (author)
  • Ardem-Jones, A.Royal Marsden NHS Foundation Trust (author)
  • Bancroft, E. K.Royal Marsden NHS Foundation Trust,Institute of Cancer Research London (author)
  • Bangma, C.Erasmus University Medical Center (author)
  • Castro, E.Institute of Cancer Research London,Spanish National Cancer Research Center (CNIO) (author)
  • Dearnaley, D.Institute of Cancer Research London (author)
  • Eccles, D.Princess Anne Hospital (author)
  • Eeles, R. A.Royal Marsden NHS Foundation Trust,Netherlands Cancer Institute (author)
  • Evans, D. G.Manchester University NHS Foundation Trust (author)
  • Eyfjord, J.University of Iceland (author)
  • Falconer, A.Imperial College Healthcare NHS Trust (author)
  • Foster, C. S.HCA Healthcare Laboratories (author)
  • Grönberg, H.Norrland University Hospital (author)
  • Hamdy, F. C.Churchill Hospital,University of Oxford (author)
  • Johansson, O.National University Hospital of Iceland (author)
  • Khoo, V.Royal Marsden NHS Foundation Trust (author)
  • Kote-Jarai, Z.Institute of Cancer Research London (author)
  • Lilja, H.Lund University,Lunds universitet,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,Clinical Chemistry, Malmö,Lund University Research Groups,University of Tampere,University of Oxford,Memorial Sloan-Kettering Cancer Center(Swepub:lu)klke-hli (author)
  • Lubinski, J.Pomeranian Medical University (author)
  • Maehle, L.Norwegian Radium Hospital (author)
  • Melia, J.University of Cambridge (author)
  • Mikropoulos, C.Institute of Cancer Research London (author)
  • Mitchell, G.University of Melbourne,Peter MacCallum Cancer Centre (author)
  • Mitra, A. V.Institute of Cancer Research London,Royal Free Hospital (author)
  • Moss, S.Queen Mary University (author)
  • Moynihan, C.Institute of Cancer Research London (author)
  • Page, E. C.Institute of Cancer Research London (author)
  • Rennert, G.Carmel Medical Center (author)
  • Suri, M.Nottingham City Hospital (author)
  • Wilson, P.BioZenix (author)
  • Radboud University Medical CenterInstitute of Cancer Research London (creator_code:org_t)
  • The IMPACT Steering Committee

Related titles

  • In:Urologic Oncology: Seminars and Original Investigations: Elsevier BV33:5, s. 19-2021078-1439

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view